




## Large-Scale Antibody Production: Hybridoma or Recombinant?

After successful identification of a unique hybridoma for your therapeutic or diagnostic program, you need to quickly generate gram quantities for further evaluation. Here is the critical question:

What is the best production strategy?

Large-scale Hybridoma Culture or Recombinant Production



### Comparison of Key Performance Features

Features	Hybridoma	Transient TunaCHO™
Expression level	10–50 mg/L	100–500 mg/L
Scale to reach 1 gram quantity	20–100 L	2–10 L
Cost	\$\$\$	\$\$
Timeline	4–6 months*	3–4 months**
Batch-to-batch consistency	Low	High
Security of long-term supply	Unstable	Stable
Pathway to GMP production	Difficult	Straight forward
Sequence verification	Not always. Lack of protection	Yes. Early patent protection

\*Hybridoma timeline estimates include cell line recovery, cell culture optimization, pilot production, and large-scale production.

\*\*Transient recombinant TunaCHO timeline estimates include hybridoma sequencing, gene synthesis and cloning, pilot production, and large-scale production.

**The choice is clear: go with recombinant TunaCHO!**

TunaCHO is a proprietary transient production platform developed by LakePharma. To learn more, visit: <https://lakepharma.com/technology/tunacho/overview>



Contact Us

Corporate Headquarters  
201 Industrial Road  
San Carlos, CA 94070

Tel. 650-288-4891  
Tel. 888-406-5658 (Toll-free)  
Fax 888-635-3618

Email [inquiries@lakepharma.com](mailto:inquiries@lakepharma.com)  
Web [www.lakepharma.com](http://www.lakepharma.com)